Regulation of melanoma cellular plasticity by the Mediator complex drives therapeutic resistance
RNA-seq (gene expression) · human · 66 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- MelanomaThis series is part of our curated briefing on it.
- Samples
- 66 samples: 22 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE316474_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1402975 and SRA study SRP662223. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 66 samples.
How we read this: 22 replicated groups read from 66 sample titles; they account for 66 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9453651 A375_GFPsg_DMSO rep1 A375_GFPsg_DMSO
- GSM9453652 A375_GFPsg_DMSO rep2 A375_GFPsg_DMSO
- GSM9453654 A375_GFPsg_DMSO rep3 A375_GFPsg_DMSO
- GSM9453656 A375_GFPsg_Vemu rep1 A375_GFPsg_Vemu
- GSM9453658 A375_GFPsg_Vemu rep2 A375_GFPsg_Vemu
- GSM9453660 A375_GFPsg_Vemu rep3 A375_GFPsg_Vemu
- GSM9453662 A375_MED12sg1_DMSO_rep1 A375_MED12sg1_DMSO
- GSM9453664 A375_MED12sg1_DMSO_rep2 A375_MED12sg1_DMSO
- GSM9453666 A375_MED12sg1_DMSO_rep3 A375_MED12sg1_DMSO
- GSM9453668 A375_MED12sg1_Vemu_rep1 A375_MED12sg1_Vemu
- GSM9453670 A375_MED12sg1_Vemu_rep2 A375_MED12sg1_Vemu
- GSM9453672 A375_MED12sg1_Vemu_rep3 A375_MED12sg1_Vemu
- GSM9453674 A375_MED12sg2_DMSO_rep1 A375_MED12sg2_DMSO
- GSM9453676 A375_MED12sg2_DMSO_rep2 A375_MED12sg2_DMSO
- GSM9453678 A375_MED12sg2_DMSO_rep3 A375_MED12sg2_DMSO
- GSM9453680 A375_MED12sg2_Vemu_rep1 A375_MED12sg2_Vemu
- GSM9453682 A375_MED12sg2_Vemu_rep2 A375_MED12sg2_Vemu
- GSM9453684 A375_MED12sg2_Vemu_rep3 A375_MED12sg2_Vemu
- GSM9453686 A375_MED19sg1_DMSO_rep1 A375_MED19sg1_DMSO
- GSM9453688 A375_MED19sg1_DMSO_rep2 A375_MED19sg1_DMSO
- GSM9453690 A375_MED19sg1_DMSO_rep3 A375_MED19sg1_DMSO
- GSM9453692 A375_MED19sg1_Vemu_rep1 A375_MED19sg1_Vemu
- GSM9453694 A375_MED19sg1_Vemu_rep2 A375_MED19sg1_Vemu
- GSM9453696 A375_MED19sg1_Vemu_rep3 A375_MED19sg1_Vemu
- GSM9453698 A375_MED19sg2_DMSO_rep1 A375_MED19sg2_DMSO
- GSM9453700 A375_MED19sg2_DMSO_rep2 A375_MED19sg2_DMSO
- GSM9453702 A375_MED19sg2_DMSO_rep3 A375_MED19sg2_DMSO
- GSM9453704 A375_MED19sg2_Vemu_rep1 A375_MED19sg2_Vemu
- GSM9453706 A375_MED19sg2_Vemu_rep2 A375_MED19sg2_Vemu
- GSM9453708 A375_MED19sg2_Vemu_rep3 A375_MED19sg2_Vemu
- GSM9453710 A375_MED23sg1_DMSO_rep1 A375_MED23sg1_DMSO
- GSM9453711 A375_MED23sg1_DMSO_rep2 A375_MED23sg1_DMSO
- GSM9453712 A375_MED23sg1_DMSO_rep3 A375_MED23sg1_DMSO
- GSM9453713 A375_MED23sg1_Vemu_rep1 A375_MED23sg1_Vemu
- GSM9453714 A375_MED23sg1_Vemu_rep2 A375_MED23sg1_Vemu
- GSM9453715 A375_MED23sg1_Vemu_rep3 A375_MED23sg1_Vemu
- GSM9453716 A375_MED23sg2_DMSO_rep1 A375_MED23sg2_DMSO
- GSM9453717 A375_MED23sg2_DMSO_rep2 A375_MED23sg2_DMSO
- GSM9453718 A375_MED23sg2_DMSO_rep3 A375_MED23sg2_DMSO
- GSM9453719 A375_MED23sg2_Vemu_rep1 A375_MED23sg2_Vemu
+ 26 more — browse all 66 samples with per-sample file links →
- GSE230489 RNA-sequencing of cutaneous melanoma and non-small cell lung cancer biopsies 38 samples same disease briefing · shares melanoma
- GSE100797 Mutational and neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma 25 samples same disease briefing · shares melanoma
- GSE130956 Investigation of ST8SIA1 expression in icaritin-treated and untreated melanoma cell lines 12 samples same disease briefing · shares melanoma
- GSE140150 A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 has a neural crest-like phenotype and is highly metastatic in vivo 6 samples same disease briefing · shares melanoma
- GSE300877 Diverse roles of SERPINE1 in regulating cellular proliferation and invasion 6 samples same disease briefing · shares cellular
- GSE12391 Melanoma: comparison between common nevi, radial/vertical growth phase melanoma, metastases and dysplastic nevi 114 samples same disease briefing · shares melanoma
- GSE134459 Genome-wide maps of transcriptomic and epigenomic state in melanoma cell lines 73 samples same disease briefing · shares melanoma
- GSE123728 Clinical and Immunologic Activity of a Single Dose of Neoadjuvant PD-1 Blockade and Predictors of Clinical Outcomes in Resectable Melanoma 24 samples same disease briefing · shares melanoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.